ACAD Share Price

Open 37.17 Change Price %
High 37.18 1 Day -0.43 -1.16
Low 36.45 1 Week 0.09 0.25
Close 36.55 1 Month 5.47 17.60
Volume 836769 1 Year 0.57 1.58
52 Week High 40.83
52 Week Low 20.68
ACAD Important Levels
Resistance 2 37.23
Resistance 1 36.95
Pivot 36.73
Support 1 36.15
Support 2 35.87
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
HMNY 5.70 63.79%
LOCM 0.09 50.00%
VALV 0.03 50.00%
SCHS 0.04 33.33%
GCFB 0.50 31.58%
OPNT 35.70 29.54%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
ZOOM 0.00 -100.00%
TXCC 0.01 -95.00%
AMCF 0.01 -80.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
BDMS 4.10 -45.33%
More..

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)

ACAD Technical Analysis 5
As on 19th Sep 2017 ACAD Share Price closed @ 36.55 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 30.94 & Strong Buy for SHORT-TERM with Stoploss of 31.79 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACAD Target for September
1st Target up-side 39.37
2nd Target up-side 42
3rd Target up-side 44.63
1st Target down-side 31.85
2nd Target down-side 29.22
3rd Target down-side 26.59
ACAD Other Details
Segment EQ
Market Capital 128332624.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.acadia-pharm.com
ACAD Address
ACAD
11085 Torreyana Road
Suite 100
San Diego, CA 92121
United States
Phone: 858-558-2871
Fax: 858-558-2872
ACAD Latest News
Interactive Technical Analysis Chart ACADIA Pharmaceuticals Inc. ( ACAD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ACADIA Pharmaceuticals Inc.
ACAD Business Profile
ACADIA Pharmaceuticals Inc., incorporated in 1993, is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831. The Company used its drug discovery platform to discover additional product candidates. These include two preclinical programs that provide the potential for disease-modifying therapies for treating Parkinson’s disease and other neurological disorders. Corporate Headquarters of the Company is at 11085 Torreyana Road, Ste. 100, San Diego, CA 92121-1104.